Integration of Follow-up by First and Second Line Practitioners by Telemonitoring in Heart Failure.
NCT ID: NCT01696890
Last Updated: 2015-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
50 participants
INTERVENTIONAL
2011-10-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heart Failure Events Reduction With Remote Monitoring and eHealth Support Investigator Initiated Trial
NCT03663907
Tele-HF: Yale Heart Failure Telemonitoring Study
NCT00303212
Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.
NCT01495078
Geriatric-CO-mAnagement for Cardiology Patients in the Hospital
NCT02890927
A Two-way Communication System to Coach Elderly Patients With Heart Failure
NCT03294811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Very recently, our study group showed that an intense collaboration between first line practitioner and heart failure clinic, facilitated by the use of telemonitoring, can reduce mortality and hospitalisation rate. This study was a RIZIV sponsored trial of 6 months follow-up in patients with chronic heart failure. However, a large randomised multicentre trial investigating the use of telemonitoring in a population of heart failure (NYHA II-III) patients did not find any difference between telemonitoring and usual care (Chaudry et al NEJM 2010). In contradiction with this study, a Cochrane meta-analysis (Ingliss 2010) in more than 5000 patients confirmed our finding with a reduction in mortality and morbidity. The question therefore remains which factors are responsible for success or failure of the use of telemonitoring. Based on our previous experience, the approach of close monitoring by telemonitoring, with first line intervention by the patient's general practitioner (GP) and supervision by the heart failure clinic, might be the critical success factor.
Therefore, the aim of this study is to evaluate this model of telemonitoring-assisted close supervision and interaction between first and second line health professionals versus a model of telemonitoring without this integrated approach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
integrated care
telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
integrated follow-up
close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
standard care
telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
standard care
no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
integrated follow-up
close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
standard care
no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LVEF \< 40% during hospitalization.
Exclusion Criteria
* heart failure due to severe aortic stenosis
* participation in cardiac rehabilitation after discharge
* previous or actual residency in a nursing home
* creatinine clearance \<15 ml/min
* planned dialysis in the next 6 months
* planned biventricular pacemaker or cardiac surgery
* life expectancy of less than 1 year due to other diseases
* severe obstructive pulmonary disease (Gold III)
* significant mental or cognitive problems interfering with the daily measurements or intake of medication.
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul Dendale
Prof Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
paul dendale, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Jessa Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Middelheim Ziekenhuis
Antwerp, , Belgium
UZ Brussel
Brussels, , Belgium
Ziekenhuis Oost-Limburg
Genk, , Belgium
AZ Maria Middelares
Ghent, , Belgium
Jessa Hospital
Hasselt, , Belgium
AZ Groeninge
Kortrijk, , Belgium
Chr.Citadelle
Liège, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEMAHF2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.